Methods are described to reduce risk of or prevent wooden chest syndrome or other respiratory effects arising from exposure to fentanyl or a fentanyl analog, for instances inpatients receiving medically assisted treatment (MAT) for Opioid Use Disorder (OUD) or who are receiving analgesia and pain management with F/FAs. Pharmaceutical compositions for use in such methods are described.

In one configuration, a handheld compound tester to process and detect presence of a compound in a tablet is disclosed. The handheld compound tester may include a sampling chamber configured to receive a tablet and a lid couplable with the sampling chamber. The coupling of the lid with the sampling chamber may cause cutting of the tablet. A liquid may be added inside the sampling chamber to create a mixture with segments of the tablet. The mixture may be then received by a housing adjoining the sampling chamber. A test strip disposed within the housing, upon contacting the mixture, may be configured to indicate a presence of the compound in the mixture.

The present invention relates to novel 6-acetylmorphine analogs, and methods for their synthesis and use. Such analogs are designed to provide a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.

The present invention discloses a highly efficient method for detecting opioids, opiates, cannabinoids, or benzodiazepines present in a sample, comprising the steps of adding to said sample an enzyme with β-glucuronidase activity originated from genus Brachyspira or any mutant derived thereof; incubating the sample with the enzyme; and detecting said opioids, opiates, cannabinoids, or benzodiazepines by means of a suitable technique.

Materials and methods for testing unknown substances for the presence of an opioid are described.

The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2′,6′-dimethyltyrosine (Dmt) residue in place of the N-terminal tyrosine residue a position 1. These peptide analogs exhibit increased solubility compared to similar tetrapeptide analogs while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

The present disclosure provides isolated antibodies that bind to acetaminophen-protein adducts that are useful in the detection and diagnosis of acetaminophen-induced toxicity.

Compositions, methods, and kits are disclosed directed at haptens, immunogens and immunoassays for oxycodone and metabolites thereof. The compounds are exemplified by compounds of the Formula I. The method comprises providing in combination in a medium (i) a sample suspected of containing oxycodone and/or oxycodone metabolites, a compound of the Formula I wherein R.sup.4 or R.sup.5 is a label, and an antibody for oxycodone or a metabolite thereof. The medium is examined for the presence of a complex comprising the labeled compound of Formula I where the presence of such as complex indicates the presence of oxycodone or oxycodone metabolite in the sample.

The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic analogs of endomorphin. These peptide analogs exhibit decreased tolerance relative to morphine, increased solubility compared to similar tetrapeptide analogs, while maintaining favorable or improved therapeutic ratios of analgesia to side effects.

Components for enabling immunodection of MT-45 are described including immunogens, antibodies derived from the immunogens, immunoassay methods, detecting agents and kits.